Global Neurodegenerative Diseases Therapeutics Market 2018-2022| Increase in Aging Population to Drive Growth| Technavio
LONDON--(BUSINESS WIRE)--Dec 31, 2018--Technavio’s global neurodegenerative diseases therapeutics market research report forecasts the market to grow at a CAGR of nearly 8% during the forecast period.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181231005071/en/
Technavio predicts the global neurodegenerative diseases therapeutics market to grow at a CAGR of nearly 8% by 2022. (Graphic: Business Wire)
The increase in aging population will be one of the major trends in the during 2018-2022. Globally, there is an increase in the aging population due to declining fertility and increasing longevity. Medicine has prolonged the morbidity phase. This has increased the risk of developing neurological disorders such as Alzheimer’s disease and Parkinson’s disease. As per the United Nations, around 962 million people globally were reported to be aged 60 years in 2017.
According to Technavio analysts, one of the key drivers for the global neurodegenerative diseases therapeutics market is the strong drug development pipeline:
Global neurodegenerative diseases therapeutics market: Strong drug development pipeline
Globally, the prevalence and incidence of neurodegenerative diseases are increasing. For instance, according to the CDC, Alzheimer’s disease affected around five million people in the US in 2014 and is expected to nearly triple to 14 million people by 2060. The major neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis.
According to a senior analyst at Technavio for research on infectious and rare diseases, “The incidence of Alzheimer’s disease and Parkinson’s disease has been increasing rapidly. Thus, ongoing developments in the market are focused on R&D, which has led to a strong drug development pipeline. There are several drugs in the pipeline that could contribute to the growth of the market during the forecast period.”
Global neurodegenerative diseases therapeutics market: Segmentation analysis
This global neurodegenerative diseases therapeutics market analysis report provides market segmentation by indication (multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and others) and by region (the Americas, APAC, and EMEA). This report provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Of the four major segments by indication, the multiple sclerosis segment held the largest neurodegenerative diseases therapeutics market share in 2017, contributing to over 41% of the market. This segment will dominate the global market throughout the forecast period.
The Americas held the largest share of the market in 2017, accounting for close to 52% share. It was followed by EMEA and APAC respectively. The Americas is expected to dominate the market throughout the period 2018-2022.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181231005071/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 12/31/2018 08:00 AM/DISC: 12/31/2018 08:01 AM